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Abstract  (53 words) 
 
 
Recent progress in discovery, development and evaluation of new drugs and combination 
regimens for drug-resistant tuberculosis and more collaborative approaches by pharma, 
funders, advocates and researchers provides renewed hope for overcoming the challenges of 
improving the high death rates, reducing duration of therapy, improving patient adherence and 
curtailing the global spread of drug resistance.  
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Tuberculosis (TB) remains a global emergency and is now the most important infectious 
disease cause of death.  In 2016, 10.4 million people developed active tuberculosis, of whom 1.7 
million died.   An estimated 490,000 had multi-drug-resistant TB (MDR-TB and 6% had 
extensively-drug-resistant (XDR) TB.  Currently available treatment regimens cure just over 
50% of patients with MDR-TB, and only 30% of XDR-TB patients.  These regimens are of long 
duration, have severe and at times irreversible side effects, and are associated with poor patient 
adherence, treatment failure, further acquisition of drug resistance, and high mortality.  The 
novel and repurposed TB drug and combination regimen development pipeline has grown in 
recent years, spearheaded by the regulatory approval of two novel drugs, the diarylquinoline 
bedaquiline in 2012 and the nitroimidazole delamanid in 2014. 
 
Growing pipeline of new TB drugs           
Recent concerted efforts of funders, pharma, advocates and researchers are accelerating 
development of new drugs and regimens for DR-TB (Supplemental Figure 1).  Currently 17 
new anti-TB drugs, including bedaquiline and delamanid, that are currently being studied in 
phase 1, 2, or 3 trials or that will enter phase 1 trials in 2018 (Supplemental Table 1).  These 
drugs target mycobacterial energy production (diarylquinolines, imidazopyridines, 
riminophenazines); cell wall synthesis and energy production (nitroimidazoles, with differing 
actions in replicating vs. persistent bacilli); cell wall synthesis (ethylene diamines, DrpE1 
inhibitors, including the benzothiazinones); or mycobacterial protein synthesis (oxazolidinones, 
oxaboroles – a new class, and carbo-styril derivatives).    
Repurposed drugs which are being included in several regimens for DR-TB include:  clofazimine 
(a riminophenazine traditionally used to treat leprosy, prolonged use of which can lead to 
irreversible skin discolouration), levofloxacin or moxifloxacin (fluoroquinolones, often used for 
respiratory and other infections, with increasing prevalence of resistance), linezolid (an 
oxazolidinone developed for skin and soft tissue infections, with dose- and duration-dependent 
bone marrow and nerve toxicity), and pyrazinamide (for which point-of-care resistance testing 
is not readily available).   
 
New combination regimens - trials and tribulations 
Since 2012, eleven phase 2 or 3 clinical trials of new drugs and regimens for DR-TB have been 
initiated, some with support from pharma (Supplemental Table 2).  The Global Alliance for TB 
Drug Development has prioritized development of a common design is to randomize 
participants with DS-TB to two or more arms and to enrol participants with DR-TB in a single 
arm, possibly with an additional drug or a longer duration of treatment.  The phase 2 NC-005 
trial, begun in November 2014, contained a DR-TB arm with bedaquiline, pretomanid, 
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moxifloxacin and pyrazinamide.  Final results are expected later in 2018.   The phase 3 NC-006 
or STAND trial, begun in February 2015, enrolling participants with DR-TB to 6 months of 200 
mg daily pretomanid (vs. two lower doses of daily pretomanid in the two DS-TB arms), 
moxifloxacin and pyrazinamide.  The study was put on hold in October 2015 after 3 participants 
developed severe hepatotoxicity.   Follow-up of all 284 participants is continuing and will end in 
May 2018.   After the accrual hold was lifted in 2016, the TB Alliance decided not to reopen 
STAND, and shifted their focus to developing regimens containing both bedaquiline and 
pretomanid.   The single-arm NiX-TB trial, begun in March 2015 in persons with XDR-TB, 
reported dramatic preliminary results in 2017 with a high rate of relapse-free cure and low 
rates of mortality and irreversible toxicity after 6 to 9 months of treatment with bedaquiline, 
pretomanid, and high dose linezolid (which was dose-adjusted following toxicity).  In November 
2017, the TB Alliance closed accrual to NiX and transitioned to NC-007 or ZeNiX, a phase 3 four-
arm trial of bedaquiline, pretomanid, and linezolid, testing two doses (1200 mg or 600 mg) and 
durations (6 months or 2 months) of daily linezolid in 180 persons with XDR-TB.   The NC-008 
or SimpliciTB trial will open in August 2018 enrolling 150 DS-TB participants to 4 months of 
bedaquiline, pretomanid, moxifloxacin, and pyrazinamide vs. standard 6 months of therapy, and 
a DR-TB arm with 6 months of the same four drugs.   Data are being collated on long-term safety 
outcomes in participants who have received bedaquiline both receiving the drug both in clinical 
trials or through compassionate use/expanded access programs.   There is increasing assurance 
that there is no signal for increased risk of mortality, though pharmacovigilance will continue 
considering the drug’s long half-life and prolongation of the Qtc. 
There are several other ongoing trials of bedaquiline and delamanid in new combination 
regimens in patients with MDR- and XDR-TB.   The phase 2/3 NExT-5001 trial, opened in 
October 2015 in Cape Town, South Africa, randomizing participants to bedaquiline, linezolid, 
levofloxacin, pyrazinamide for 6 to 9 months vs. other non-bedaquiline-containing regimens.   
Unitaid with Partners in Health at Harvard and Médicins sans Frontières (MSF) began the phase 
3 endTB trial in December 2016, an all-oral five-arm adaptive design study of various 
combinations of 9 months of bedaquiline, linezolid, moxifloxacin, clofazimine, and delamanid in 
750 participants with fluoroquinolone-sensitive MDR-TB in Georgia, Kazakhstan, Kyrgyzstan, 
Lesotho and Peru.    TB-PRACTECAL is a two-stage 5-arm phase 2/3 study begun in January 
2017 of 6 months of various combinations of bedaquiline, pretomanid, moxifloxacin, linezolid, 
and clofazimine compared to standard WHO treatment, conducted by MSF in 630 participants 
with MDR or XDR-TB in Belarus, South Africa, and Uzbekistan. 
Otsuka completed its phase 3 trial of 6 months of delamanid in addition to background regimen 
in June 2016 and reported results in November 2017 confirming efficacy and an improved 
safety profile over phase 2 trial results.    The endTB trial includes delamanid in two arms, with 
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and without bedaquiline, with results expected in September 2021.    AIDS Clinical Trials Group 
protocol A5343 assesses Qtc prolongation, safety, tolerability, and pK of bedaquiline and 
delamanid and will complete accrual in 2018.    Such drug-drug interaction (DDI) studies are 
critical to document safety to study participants and patients as new TB drugs are included in 
large phase 3 trials and rolled out in country programmes. 
 
Alternate approach to developing MDR-TB regimens 
In October 2016, WHO updated guidelines for treatment of drug-resistant TB, recommending a 
shorter regimen of 9 -12 months in patients with no documented resistance to fluoroquinolones 
or second-line injectables, rather than the standard 20-month treatment.  This change was 
based in part on results from a prospective observational study in Bangladesh aiming to 
develop a safer, more patient compliant, effective, and inexpensive regimen. Moving away from 
classic single drug evaluation, the study used treatment outcomes and drug side effects to make 
adjustments in individual drug components of standard MDR-TB treatment regimen. The  9-
month ‘Bangladesh regimen’ led to the STREAM trial, a phase 3 non-inferiority trial began in 
July 2012, treated with either 9 months of moxifloxacin, clofazimine, pyrazinamide and 
ethambutol and 4 months of high-dose isoniazid, injectable kanamycin, and prothionamide or 
the WHO standard of care.   
Given the limitations of evaluating single drugs, and the success of the Bangladesh, a regimen-
based approach is now favored in which new, old and re-purposed drugs are given in various 
combinations in order to identify a drug combination that can be used for treating TB and MDR-
TB. Janssen Pharmaceuticals partnered with STREAM investigators to launch Stage 2 in April 
2016, adding two new arms containing either 6 or 9 months of bedaquiline with a new target 
accrual of 1,155.    STREAM Stage 1 trial preliminary results (November, 2017) indicate that the 
shorter regimen was almost as effective as the standard WHO regimen, though the lower 
confidence interval just crossed the margin of non-inferiority.   STREAM Stage 2 is the largest 
trial of DR-TB ever to be conducted and is the first phase 3 randomized trial of bedaquiline.  
Results are expected in 2021. 
 
Latent TB Infection 
Novel regimens to prevent development of TB in persons with latent TB infection are being 
tested. Three randomized controlled trials of treatment of latent TB infection (LTBI) in close 
contacts of patients with DR-TB are underway in both children and adults, comparing 6 months 
of daily levofloxacin vs. placebo or 6 months of daily delamanid vs. 9 months of daily isoniazid.  
As the incidence of DR-TB increases, so does the risk of transmission of resistant organisms to 
others, particularly young children.   
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Advances in pre-clinical and early developmental pipelines 
A number of new drugs are in late pre-clinical and early clinical development and have 
improved potency, bioavailability, and less toxicity than previous agents in their class 
(Supplemental Table 1).   New agents targeting mycobacterial energy production, include the 
imidazopyridine Q203, which has completed phase 1 testing and enters phase 2 trials 
conducted by the PanACEA consortium in 2018.    A new riminophenazine, TBI-166, developed 
by Institute Materia Medica in Beijing, China, will entire phase 1 testing as a less toxic 
alternative to clofazimine.   A new potent new diarylquinoline, TBAJ-587, which has less Qtc 
prolongation than bedaquiline is being developed by The TB Alliance.     
SQ109 is an ethylene diamine (same class as ethambutol), an inhibitor of cell wall synthesis, 
that was studied in the PanACEA MAMS-TB-01 trial of high-dose rifampicin, in which the two 
SQ109 arms were dropped before the trial was completed.  Sequella has partnered with Infectex 
to conduct larger phase 2/3 studies at sites in Russia.    
More promising is the development of four new DprE1 inhibitors of cell wall synthesis.   
PBTZ169, a benzothiazinone developed by Nearmedic, is entering phase 2 trials conducted by 
iM4TB based in Switzerland with funding from the Bill and Melinda Gates Foundation (BMGF).   
The TB Alliance will begin phase 1 trials of TBA7371 in 2018.   Otsuka, with funding from BMGF, 
have phase 1 trials of OPC-0167832, for demonstrating synergy with delamanid.    PanACEA 
consortium are planning phase 1 trials of BTZ-043, a benzothiazinone developed at the 
University of Munich. 
Four new oxazolidinones and an oxaborole, an entirely new class of anti-TB drug are among the 
new agents that target mycobacterial protein synthesis.   Sequella and now the TB Alliance are 
collaborating to renew commercial development of the oxazolidinone, Sutezolid, (initially 
developed by Pfizer) which appears to be much less toxic and more tolerable than linezolid.   
LegoChem Biosciences has begun phase 2 trials of delpazolid (LCB01-0371).   MicuRX is in 
phase 1 trials of contezolid.   The TB Alliance will begin phase 1 studies of Institute Materia 
Medica’s TBI-223.  Finally, GlaxoSmithKline will begin phase 2 studies of GSK 3036656, an 
oxaborole that is potent in combination with bedaquiline and pretomanid.  All of these new 
agents in early clinical development offer the promise of greater potency, safety and tolerability, 
and reduced drug-drug interactions that may greatly expand the horizon of effective 
combination treatment for all forms of TB. 
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Unmet and longer-term needs 
Despite good progress in the TB drug pipeline  there remain several key unmet needs and 
challenges: drug-resistant TB needs a more effective fully oral, shorter, less toxic and safer 
therapy; HIV co-infection needs minimal TB drug  interactions with antiretrovirals; latent TB 
infection needs shorter and safer therapy; and  accurate information is also required on drug–
drug interactions, and their use in specific patient groups, such as children, HIV-co-infected 
individuals and pregnant women. Furthermore, there are up to 2 billion people with latent 
Mycobacterium tuberculosis (Mtb) infection (LTBI) of which between 5–15% will progress to 
develop active TB disease during their lifetime due to a range of risk factors including lower 
socioeconomic groups, homelessness, HIV, and immunosuppression due to any cause including 
HIV and renal transplantation.  The mechanisms of antibiotic tolerance and survival of the 
bacteria in macrophages remain to be defined, and developing a means of inhibition requires 
investigation. Development of effective new TB drugs  will need to define dynamic nature of the 
host–pathogen interaction during latent TB infection, identification of specific bacterial and host 
markers of this progression and the determinants of progression  to active TB disease. 
 
As more drug candidates become available for evaluation in trials, increased investments are 
required for:   basic TB drug research discovery  such as high throughput screening to find lead 
compounds acting against well-validated Mycobacterium tuberculosis targets; taking promising 
leads and expand the pipeline and facilitating  promising new compounds from the preclinical 
to the clinical stages of development; defining new biomarkers for early prediction of  long-term 
treatment outcome  for accelerating clinical development and evaluation of short regimens 
using novel trial designs, and predicting quantitative relationships between phase 2 readouts of 
sputum culture conversion, phase 3 readout of cure, and duration of therapy. More creative 
solutions for efficient clinical trial designs and creative ways to test “new regimens” not just one 
drug at a time, are required.  
 
Inadequate global capacity to perform controlled clinical trials to support registration of new 
regimens for treatment of tuberculosis in high-TB endemic regions is becoming problematic as 
more drug candidates progress into clinical trials. Phase 3 trials are always complex, expensive, 
and take longer to complete than anyone expected. Major limitation of TB drug development 
research and trials is the continuing dominance by western groups, the lack of funding, 
inadequate human capacity and required expertise, poor  infrastructure,  and limited career 
opportunites. Capacity building and knowledge transfer, infrastructure upgrading to   good 
clinical and good laboratory practice standards is required and   international agencies, national 
governments and communities should come together to develop innovative funding and market 
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incentive mechanisms to promote and support new TB drug development and rapid adoption of 
new regimens which provide a net overall benefit to the patient, and health service. 
   
Concluding remarks 
There has been good progress since 2012 in development of new and repurposed TB drugs and 
combination regimens enriching the phase 1/2/3 trials pipeline.  Whilst collaborative work 
between researchers, pharma and funders is increasing,  vital  challenges remain.    The 
fragmentation of TB drug development and research  together with inadequate investments in 
TB drug trials capacity high TB endemic countries leaves major gaps in coordination  between 
TB stakeholders globally.   Recent  increase in political will arising from the Moscow declaration 
to end TB and the forthcoming United Nations General Assembly high-level meeting on TB in 
September 2018  brings renewed hope for increased resources for TB drug development  
through innovative financing mechanisms.    
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Supplemental Table l 
 
New TB drugs in clinical development 
 
Drug Class Mechanism of Action Evaluation 
Phase 
Notes  
[sponsor] 
Target:   Energy 
 
Bedaquiline 
(TMC-207, Sirturo) 
 
 
Diarylquinoline 
  
 
 
Inhibits ATP synthase 
and bacterial 
respiration 
 
Phase 3 
 
Conditional marketing 
approval, long half-life, 
ECG Qtc prolongation 
 
[Janssen, TB Alliance, 
NIAID, SAMRC, the Union, 
Unitaid, USAID] 
 
 
Q203 
 
 
Imidazopyridine 
 
 
 
 
Inhibits mycobacterial 
QcrB cytochrome and 
bacterial respiration 
 
Phase 1/2 
 
Phase 1 studies underway, 
phase 2 studies planned 
for 2018, long half-life 
 
[Qurient, Infectex, 
PanACEA] 
 
TBI-166 
 
 
Riminophenazine Inhibits ion transport 
and bacterial 
respiration 
Phase 1 Potentially less toxic 
alternative to clofazimine 
 
[Institute of Materia 
Medica] 
 
 
TBAJ-587 
 
 
Diarylquinoline Inhibits ATP synthase 
and bacteria respiration 
Pre-Phase 1 IND filing late 2018, 
greater potency/efficacy, 
less Qtc prolongation than 
bedaquiline 
 
[Janssen, Merck, TB 
Alliance] 
Target:   Cell Wall Synthesis and Energy 
Delamanid 
(OPC-67683) 
 
Nitroimidazole 
 
Inhibits cell wall 
synthesis and bacterial 
respiration 
Phase 3 Conditional marketing 
approval, phase 3 trial 
showed efficacy and 
better safety profile, twice 
daily oral dosing 
 
[Otsuka, NIAID, Unitaid] 
 
Pretomanid 
(PA-824) 
 
 
Nitroimidazole 
 
Inhibits cell wall 
synthesis and bacterial 
respiration 
Phase 3 Potent bactericidal and 
sterilizing activity in 
murine models  
 
[TB Alliance] 
Target:  Cell Wall Synthesis 
SQ109 
 
 
1,2-ethylene 
diamine 
Inhibits cell wall 
synthesis 
(MmpL3) 
Phase 2/3 Possible synergy with 
bedaquiline 
 
[Sequella, Infectex, 
PanACEA] 
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PBTZ169 
 
 
DprE1 inhibitor Inhibits cell wall 
synthesis 
 
Phase 2 Benzothiazinone, synergy 
with bedaquiline and 
clofazimine 
 
[Nearmedic, iM4TB, 
BMGF] 
 
TBA7371 
  
 
DprE1 inhibitor Inhibits cell wall 
synthesis 
Phase 1 Potential to shorten 
treatment for all TB, 
phase 1 trials underway 
 
[TB Alliance] 
 
OPC-167832 
 
(Carbostyril base) 
DprE1 inhibitor Inhibits cell wall 
synthesis 
Phase 1 3,4-carbostyril derivative, 
Synergy with delamanid 
 
[Otsuka, BMGF] 
 
BTZ 043 
 
DprE1 inhibitor Inhibits cell wall 
synthesis 
Phase 1 Benzothiazinone, synergy 
with rifampicin, low 
toxicity, no interaction 
with hepatic enzymes 
 
[University of Munich, 
PanACEA] 
Target:  Protein Synthesis 
 
Sutezolid 
(PNU-100480) 
 
 
Oxazolidinone 
 
Inhibits protein 
synthesis (23S 
ribosome) 
 
Phase 1/2 
 
Potentially less toxic than 
linezolid, renewed 
commercial development 
 
[Pfizer then Sequella, TB 
Alliance] 
 
Delpazolid 
(LCB01-0371) 
 
Oxazolidinone Inhibits protein 
synthesis (23S 
ribosome) 
 
 
 
 
Phase 2 Potentially less toxic and 
more potent than 
linezolid 
 
[LegoChem Biosciences] 
GSK 3036656 
(GSK 070) 
 
Oxaborole 
 
Inhibits protein 
synthesis  
(leucyl-tRNA 
synthetase) 
Phase 2a New chemical class, low 
oral daily dose, potent 
with bedaquiline/ 
pretomanid, phase 2a 
studies mid-2018 
 
[GSK] 
 
Contezolid 
(MRX-4/MRX-1) 
 
 
 
Oxazolidinone Inhibits protein 
synthesis (23S 
ribosome) 
Phase 1 Potentially less toxic than 
linezolid 
 
[MicuRX] 
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TBI-223 
 
  
Oxazolidinone Inhibits protein 
synthesis 
(23S ribosome) 
Pre-Phase 1 IND filing late 2018, 
potent, bioavailable, oral 
single daily dose, no 
interaction with hepatic 
enzymes, no bone 
marrow toxicity (animal 
studies) 
 
[Institute of Materia 
Medica, TB Alliance] 
 
 
Abbreviations: BMGF: Bill and Melinda Gates Foundation; GSK: GlaxoSmithKline PLC; iM4TB:  
Innovative Medicines for Tuberculosis (Switzerland); NIAID: National Institute of Allergy and 
Infectious Diseases (US); PanACEA: Pan African Consortium for the Evaluation of Antituberculosis 
Antibiotics; SAMRC: South African Medical Research Council;  The Union: International Union 
Against Tuberculosis and Lung Disease; USAID: U.S. Agency for International Development
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Supplemental Table 2 
Advanced-stage clinical trials of new regimens for drug-resistant TB 
 
Trial Name 
 
NCT Number  
Experimental Arm(s)  Target 
Accrual  
Trial 
Phase  
Study Start and 
Completion Dates  
Otsuka 213 
 
NCT01424670 
DLM + OBR 511 3 
Sep 2011 –Jun 2016 
(results announced 
IUATLD Oct 2017) 
STREAM Stage 1 
 
NCT02409290 
MOX, CFZ, EMB, PZA, INH, 
   KAN, PRO 
424 3 
Jul 2012 –Jul 2018 
(interim results 
announced IUATLD  
Oct 2017) 
NC-005 
 
NCT02193776 
BDQ, PRE, MOX, PZA 60 2 Nov 2014 –Mar 2018 
NC-006 STAND 
 
NCT02342886 
PRE, MOX, PZA 
13 
(of 300) 
3 
Feb 2015 –Mar 2018 
(accrual stopped early 
October 2015) 
NiX-TB 
 
NCT02333799 
BDQ, PRE, LZD 
109 
(of 200) 
3 
Mar 2015 –Nov 2017 
(transition to ZeNiX) 
NExT-5001 
 
NCT02454205 
BDQ, LZD, LVX, PZA +  
   [ETH or INH or TRZ] 
300 2/3 Oct 2015 –Jan 2019 
MDR-END 
 
NCT02619994 
DLM, LZD, LVX, PZA 238 2 Jan 2016 –Dec 2019 
STREAM Stage 2 
 
NCT02409290 
MOX, CFZ, EMB, PZA, INH, 
   KAN, PRO 
BDQ, CFZ, LVX, EMB, PZA, 
   INH, PRO 
BDQ, CFZ, LVX, PZA, INH, 
   KAN 
1155 3 Apr 2016 –Apr 2021 
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endTB 
 
NCT02754765 
There are 5 experimental 
arms, three with bedaquiline  
and three with delamanid 
(one arm with both).   
BDQ, LZD, MOX, PZA 
BDQ, LZD, LVX, PZA, CFZ  
BDQ, LZD, LVX, PZA, DLM 
DLM, LZD, LVX, PZA, CFZ 
DLM, MOX, CFZ, PZA 
750 3 Dec 2016 –Sep 2021 
TB-PRACTECAL 
 
NCT0258972 
BDQ, PRE, LZD, MOX 
BDQ, PRE, LZD, CFZ  
BDQ, PRE, LZD 
630 2/3 Jan 2017 –Mar 2021 
NC-007 ZeNiX  
 
NCT03086486 
BDQ, PRE, LZD (dose range) 180 3 Nov 2017 –Jan 2022 
NC-008 
SimpliciTB  
 
 
NCT03338621 
BDQ, PRE, MOX, PZA 150 2c/3 Aug 2018 –Mar 2022 
 
Abbreviations: 
BDQ: bedaquiline; CFZ: clofazimine; DLM: delamanid; EMB:  ethambutol; ETH: ethionamide; 
INH: isoniazid;  IUATLD:   International Union against TB and Lung Disease Conference, 
Guadalajara, Mexico, October, 2017; KAN: kanamycin (injectable); LVX: levofloxacin; LZD: 
linezolid; MOX: moxifloxacin; OBR: optimized background regimen; PRE: pretomanid; PRO: 
prothionamide; PZA: pyrazina 
